KR20210018193A - 선택적 syk 억제자의 사용 방법 및 약학적 조성물 - Google Patents

선택적 syk 억제자의 사용 방법 및 약학적 조성물 Download PDF

Info

Publication number
KR20210018193A
KR20210018193A KR1020207028762A KR20207028762A KR20210018193A KR 20210018193 A KR20210018193 A KR 20210018193A KR 1020207028762 A KR1020207028762 A KR 1020207028762A KR 20207028762 A KR20207028762 A KR 20207028762A KR 20210018193 A KR20210018193 A KR 20210018193A
Authority
KR
South Korea
Prior art keywords
weight
compound
eye
ophthalmic composition
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020207028762A
Other languages
English (en)
Korean (ko)
Inventor
안잘리 판데이
매튜 채핀
해롤드 패터슨
융 웨 쉬
마크 아벨슨
Original Assignee
포톨라 파마슈티컬스, 인코포레이티드
오라, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 포톨라 파마슈티컬스, 인코포레이티드, 오라, 인코포레이티드 filed Critical 포톨라 파마슈티컬스, 인코포레이티드
Publication of KR20210018193A publication Critical patent/KR20210018193A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207028762A 2018-03-09 2019-03-08 선택적 syk 억제자의 사용 방법 및 약학적 조성물 Pending KR20210018193A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862641094P 2018-03-09 2018-03-09
US62/641,094 2018-03-09
US201862663999P 2018-04-27 2018-04-27
US62/663,999 2018-04-27
PCT/US2019/021402 WO2019173744A1 (en) 2018-03-09 2019-03-08 Methods of use and pharmaceutical compositions of a selective syk inhibitor

Publications (1)

Publication Number Publication Date
KR20210018193A true KR20210018193A (ko) 2021-02-17

Family

ID=65818744

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207028762A Pending KR20210018193A (ko) 2018-03-09 2019-03-08 선택적 syk 억제자의 사용 방법 및 약학적 조성물

Country Status (15)

Country Link
US (1) US20210052582A1 (https=)
EP (1) EP3761986A1 (https=)
JP (1) JP7417531B2 (https=)
KR (1) KR20210018193A (https=)
CN (2) CN112243375A (https=)
AU (1) AU2019230220B2 (https=)
BR (1) BR112020018377A2 (https=)
CA (1) CA3093371A1 (https=)
IL (1) IL277093A (https=)
MX (1) MX2020009396A (https=)
PH (1) PH12020551418A1 (https=)
SG (1) SG11202008765UA (https=)
TW (1) TWI805705B (https=)
WO (1) WO2019173744A1 (https=)
ZA (1) ZA202005459B (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056457A2 (en) * 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
KR101454674B1 (ko) 2006-03-17 2014-10-27 존슨 앤드 존슨 비젼 케어, 인코포레이티드 산화에 불안정한 성분을 포함하는 안정화된 안과용 조성물
MX2010011463A (es) * 2008-04-16 2011-06-03 Portola Pharm Inc 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas.
SG2014015085A (en) * 2008-04-16 2014-06-27 Portola Pharm Inc 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors
KR20140103168A (ko) * 2011-12-16 2014-08-25 알러간, 인코포레이티드 폴리비닐 카프라락탐-폴리비닐 아세테이트-폴리에틸렌 글리콜 그라프트 코폴리머를 포함하는 안과 조성물
AR090650A1 (es) * 2012-04-12 2014-11-26 Alcon Res Ltd Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo
EP2897950A1 (en) * 2012-09-18 2015-07-29 Ziarco Pharma Ltd 2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors

Also Published As

Publication number Publication date
SG11202008765UA (en) 2020-10-29
US20210052582A1 (en) 2021-02-25
TWI805705B (zh) 2023-06-21
AU2019230220A1 (en) 2020-10-08
PH12020551418A1 (en) 2021-09-01
MX2020009396A (es) 2021-01-15
IL277093A (en) 2020-10-29
BR112020018377A2 (pt) 2021-03-09
AU2019230220B2 (en) 2025-01-30
CN119235862A (zh) 2025-01-03
JP2021517139A (ja) 2021-07-15
CA3093371A1 (en) 2019-09-12
EP3761986A1 (en) 2021-01-13
JP7417531B2 (ja) 2024-01-18
WO2019173744A1 (en) 2019-09-12
CN112243375A (zh) 2021-01-19
ZA202005459B (en) 2023-02-22
TW202002980A (zh) 2020-01-16

Similar Documents

Publication Publication Date Title
CN1753683B (zh) 预防和治疗不良眼部病症的眼用制剂
KR100889170B1 (ko) 안구 건조의 치료에 있어서 리멕솔론의 용도
US20210177807A1 (en) Compositions for the treatment and prevention of eyelid swelling
EP3856478A1 (en) Formulations for treatment of dry eye disease
AU2008325214A1 (en) Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
US9694003B2 (en) Formulations and methods for treating high intraocular pressure
RS59636B1 (sr) Kompozicije i postupci za nehirurško lečenje ptoze
KR20220011691A (ko) 안 질환의 치료
US20050239745A1 (en) Novel topical ophthalmic formulations
CN116437910A (zh) 含有西替利嗪和托可索仑的眼用组合物
DK3229780T3 (en) Ophthalmic composition for use in the treatment of dry eye syndrome
KR102268002B1 (ko) 효과 지속성 점안제 조성물
JP7417531B2 (ja) 選択的ｓｙｋ阻害剤の使用方法および医薬組成物
Smith et al. Tolerability, pharmacokinetics, and pharmacodynamics of a brinzolamide episcleral sustained release implant in normotensive New Zealand white rabbits
TWI896143B (zh) 一種有效延緩及治療近視的藥物組合物
RU2827551C2 (ru) Лечение заболеваний глаз

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201007

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220203

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240730

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250702